Zonisamide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
- TRADE NAME: Zonegran (Concordia)
- INDICATIONS: Epilepsy
- CLASS: Anticonvulsant (see also antiepileptic (anti-seizure)), Antiepileptic; sulfonamide
- HALF-LIFE: 63 hours
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of zonisamide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/30/2025
